In short
This article explores the ongoing clinical trials of BI 764198, a novel drug being investigated for the treatment of focal segmental glomerulosclerosis (FSGS), a type of kidney disease. The trials aim to assess the efficacy, safety, and tolerability of BI 764198 in patients with FSGS, as well as its pharmacokinetic and pharmacodynamic profile. This research could potentially lead to a new treatment option for individuals suffering from this challenging kidney condition.
At a glance
- Drug Name
- BI 764198
- Condition Studied
- Focal Segmental Glomerulosclerosis (FSGS)
- Study Design
- Multicenter, randomized, double-blind, placebo-controlled
- Treatment Duration
- 12 weeks
- Primary Endpoint
- 25% reduction in 24-hour urine protein-creatinine ratio (UPCR) at week 12
- Key Inclusion Criteria
- Adults 18-75 years, biopsy-proven FSGS or TRPC6 mutation, UPCR ≥ 1000 mg/g
- Key Exclusion Criteria
- Secondary FSGS, organ transplantation, uncontrolled hypertension
- Dosage Form
- Oral capsule
- Frequency
- Once daily
What is BI 764198?
BI 764198 is a new experimental medication being developed to treat a specific kidney disease called focal segmental glomerulosclerosis (FSGS). Its chemical name is [4-(6-aminopyridazin-3-yl)piperidin-1-yl][5-(4-fluorophenoxy)-4-methoxypyridin-2-yl]methanone. This medication is currently undergoing clinical trials to assess its effectiveness and safety in patients with FSGS.
Target Condition: Focal Segmental Glomerulosclerosis (FSGS)
Focal segmental glomerulosclerosis (FSGS) is a serious kidney disease that affects the glomeruli, which are tiny filtering units in the kidneys. In FSGS, scar tissue develops in parts of the glomeruli, impairing their ability to filter blood properly. This leads to a condition called proteinuria, where excessive amounts of protein leak into the urine.
Clinical Trial Details
A clinical trial is currently underway to evaluate BI 764198. This trial is described as a "multicenter, randomized, double-blind, parallel group, placebo-controlled study." Here are some key details about the trial:
- Duration: 12 weeks
- Main objective: To explore the efficacy of BI 764198 in reducing proteinuria (excess protein in urine)
- Secondary objectives: To investigate the pharmacokinetic profile of BI 764198 (how the drug moves through the body)
How BI 764198 Works
While the exact mechanism of action is not fully described in the trial information, BI 764198 is likely designed to target the underlying causes of FSGS or to help reduce proteinuria. The medication is being tested to see if it can effectively lower the amount of protein in the urine of patients with FSGS.
Potential Benefits
The main potential benefit being investigated is the reduction of proteinuria. The primary endpoint of the study is to determine the number of patients who achieve at least a 25% reduction in their urine protein-creatinine ratio (UPCR) after 12 weeks of treatment. This could potentially indicate an improvement in kidney function and a slowing of disease progression.
Eligibility Criteria
The trial has specific criteria for who can participate. Some key inclusion criteria are:
- Adults aged 18 to 75 years
- Diagnosed with biopsy-proven primary FSGS or documented TRPC6 gene mutation causing FSGS
- High levels of protein in the urine (UPCR ≥ 1000 mg/g)
- Stable doses of certain medications (if applicable), such as corticosteroids, ACE inhibitors, or ARBs
There are also several exclusion criteria, including certain other kidney conditions, uncontrolled high blood pressure, and use of specific medications.
Administration and Dosage
BI 764198 is administered as an oral capsule. The exact dosage is not specified in the trial information, but it is designed to be taken once daily for the 12-week study period.
Safety Considerations
As with any new medication, safety is a crucial aspect being studied in this trial. The researchers will be monitoring for any side effects or adverse reactions throughout the study period. It's important to note that as an experimental drug, not all potential risks are known at this stage.
Patients considering participation in this or any clinical trial should discuss the potential risks and benefits thoroughly with their healthcare provider.